Statistical analysis was performed using SPSS version 14.0 (SPSS, Chicago, Ill). The differences of gross morphological and histolopathological findings and lameness period among four groups were assessed using the Kruskal–Wallis test. The Mann–Whitney U test was used to compare the gross morphological and histolopathological findings and lameness period between two groups, and p-values <0.05 were considered statistically significant.
CJC-1295 is basically a peptide hormone that acts similar to growth hormone releasing hormones (GHRH). Invented by a Canadian biotechnology company called ConjuChem, it is beneficial to athletes because it can bioconjugate with circulating albumin and increase the time it can be used for medical purposes. It achieves this by preventing degradation of its amino acids. With a single dose, it can remain in the body for quite a few days and can cause the growth hormone to be released many times per day. This reduces the frequency of injections needed.
A total number of 207 AEs were reported by 36/36 subjects. All but one was of mild to moderate intensity (placebo-treated subject, soft tissue injury to left shoulder, unrelated to study treatment). No SAE occurred during the 7-day treatment and the 7-day follow-up time. The rate as well as the AE profile was comparable in the 9 mg, 27 mg AOD9604 and the placebo group. There was no observable trend between treatment groups with respect to the incidence of certain AEs, however subjects who received 54 mg AOD9604 experienced a greater number of headaches, diarrhea and flatulence.
A total number of 207 AEs were reported by 36/36 subjects. All but one was of mild to moderate intensity (placebo-treated subject, soft tissue injury to left shoulder, unrelated to study treatment). No SAE occurred during the 7-day treatment and the 7-day follow-up time. The rate as well as the AE profile was comparable in the 9 mg, 27 mg AOD9604 and the placebo group. There was no observable trend between treatment groups with respect to the incidence of certain AEs, however subjects who received 54 mg AOD9604 experienced a greater number of headaches, diarrhea and flatulence.
You’ve already learned that sufficient protein intake (above 0.5g/lb of body weight) can assist with adequate IGF-1 and growth hormone production. Whey protein provides your body with a complete profile of necessary amino acids, including leucine. Leucine is an amino acid that promotes greater muscle protein synthesis and assists the body while gaining lean muscle mass and losing fat tissue simultaneously.
CJC 1295 can be compounded in two forms (DAC and non-DAC). Drug affinity complex (DAC) prevents enzymatic degradation thus increasing the half-life. Consequently CJC 1295-DAC can be dosed as a single weekly injection. Administration of CJC 1295-DAC provides a GHRH-like stimulation around the clock. A potential drawback when using a weekly protocol can be attributed to ineffective GHRH stimulation when the body is due for a GH spike (usually 1:00am). This is referred to as a GH-bleed and the overall result is inferior to using CJC 1295-NON-DAC daily for 5 days out of 7. Therefore using CJC 1295-NON-DAC daily (between 6-8pm) provides a more effective GH spike at 1:00am.

In the multiple dose and long term studies, AOD9604 was well tolerated over the entire dose range. In none of the studies did any drug-related withdrawals or drug-related serious AEs occur. No drug related clinically significant AEs, or changes of clinical significance in vital signs, safety laboratory tests or ECGs were detected during the studies. There were no observable trends in the incidence of AEs between the 0.25 mg, 0.5 mg, 1 mg, 9 mg and 27 mg AOD9604 and placebo treatment groups. The highest dose administration (54 mg), however, was associated with an increased incidence of GI-related AEs.
To obtain the best results from a fat loss program, and the most amount of fat loss from your peptide supplementation, you should be following a diet which is high in protein, moderate in healthy fats and low in carbohydrates, and be physically active. At the very least you should be doing some high-intensity lifting a couple of times a week alongside the implementation of cardio. You should also have your hormone levels balanced to optimise your metabolism.
Resting plasma concentrations (mean±SEM) of mature ANP and Nt‐proANP were 14±2 pg/mL and 4±0.6 pg/mL at baseline. After gastric bypass surgery, the resting plasma concentrations rose to 24±5 pg/mL and 7±0.7 pg/mL for ANP and Nt‐proANP (increased by 23% and 43%), respectively (P=0.016 and 0.008). Absolute concentrations of ANP and Nt‐proANP were higher in individuals after bypass surgery at all acute time points during and after administration of intravenous saline (Figure 1A and 1B; P<0.001). A secondary analysis, adjusted for age, sex, and mean arterial pressure yielded similar results.
The lateral and medial condyles of the femur and tibia were fixed with 10% neutral buffered formalin and decalcified with 20% ethylenediaminetetraacetic acid (EDTA). Calcified condyles were embedded in paraffin, and standard frontal sections of 5 μm were prepared and stained with haematoxylin and eosin in the cartilage of the lateral part of the femoral condyle, according to gross morphological observations [14]. If the staining was not adequate, the specimen was cut at the next cartilage surface. Cartilage degradation features were analyzed using the scoring system modified by Mankin et al. [14]. Histopathological evidence of cartilage degeneration was evaluated by structural scoring (0, normal; 1, surface irregularities; 2, pannus and surface irregularities; 3, clefts to transitional zones; 4, clefts to radial zones; 5, clefts to calcified zones; and 6, complete disorganization) and cell status (0, normal; 1, diffuse hypercellularity; 2, cloning; and 3, hypocellularity) of the articular cartilage. Total score ranged from 0 (normal) to 9 (complete disorganization and hypocellularity of the articular cartilage). All sections were graded by two independent pathologists who did not have any information about the injection solutions.
Acromegaly is characterized by an excessive amount of articular cartilage in joints caused by excess GH secretion [25]. The tremendously thick articular cartilage in acromegaly can be explained by the local production of IGF-1 in cartilage cells through GH receptors [9,18]. Long-term treatment with GH might induce hypertrophy of the cartilage and changes in the joint geometry because of altered subchondral bone structures. Long-term treatment with GH by local injections may also be associated with various risks, including glucose intolerance, insulin resistance, diabetes, cancer, edema, and hypertension [26–29]. AOD9604 is not an agonist with a high affinity to the GH receptor and does not stimulate the production of IGF-1. Therefore, AOD9604 may be safer than human recombinant GH for the long-term treatment of OA.
The other submission commented on the consideration to place AOD-9604 in Appendix D. The submission supported listing in Schedule 4, but raised concerns that listing the substance in Appendix D would limit any future development work, including clinical trials that are currently being conducted on the substance. The submitter notes that there are currently 5 clinical trials notified to the TGA using this substance , with these approved clinical trials going ahead on the basis that the substance is safe for human use. Inclusion in Appendix D may place unnecessary burden on those conducting these clinical trials.
Ordered my peptides 8 weeks ago. Received them within 7 working days, and have noticed an incredible change in my lifestyle. I am sleeping better, mood has enhanced at work and i am training a lot longer during my workouts. Very happy with my results and will be using the products again for sure! Customer service was fantastic as they were very knowledgeable and the follow up phone calls were much appreciated.
×